30 closest matches · ranked by relevance
Thyroid Cancer · Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) · HRAS Mutant Tumor
Primary: Antitumor Activity by Objective Response Rate (ORR) — 0.0; 0.0; 43.5; 28.6 percentage of participants
HRAS Gene Mutation · HNSCC
Primary: Objective Response Rate (ORR) in High Variable Allele Frequency (VAF) Population, as Assessed by Independent Review Facility (IRF) — 20.0 percentage of participants
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Primary: Progression Free Survival (PFS) — 6.86; 13.00 weeks — p=0.0022
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Progression Free Survival (PFS) — 3; 6; 0; 8 Participants
KRAS NP_004976.2:p.G12R · Stage III Pancreatic Cancer AJCC v6 and v7 · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Proportion of Participants With an Objective Response (Partial Response + Complete Response) — 0; 0; 0; 0 Proportion of participants
KRAS Gene Mutation · Metastatic Non-Squamous Non-Small Cell Lung Carcinoma · Recurrent Non-Squamous Non-Small Cell Lung Carcinoma
Primary: Incidence of Dose-limiting Toxicity (DLT) of Pembrolizumab and Trametinib Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 4.0…
Colorectal Cancer
Primary: OS in Participants With Left-sided Tumors — 37.85; 34.30 Months
Non-Small Cell Lung Cancer · KRAS Mutation-Related Tumors
Primary: Objective Response Rate — 9 Participants
Lung Cancer, Non-Small Cell
Primary: Progression-Free Survival (PFS) as Assessed by the Investigator (INV) — 11.7; 11.4 Weeks — p=0.5197
Solid Tumor and Hematologic Malignancies
Primary: Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 23.1 Percentage of participants
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Primary: Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen — 0; 1; 0 Participants
PTEN Gene Mutation · PTEN Hamartoma Tumor Syndrome
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Dropout — 3; 2; 5; 2 Participants
Respiratory Distress Syndrome, Newborn
Primary: Mortality — 5; 3; 5 Participants
X-Linked Retinitis Pigmentosa
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 9 Weeks Following Administration, at Least Possibly Related to…
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Metastatic or Unresectable Cutaneous Melanoma
Primary: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 2.83; 1.51 Months — p=< 0.001
Hypophosphatasia
Primary: Change From Baseline to Week 24 for Plasma Pyridoxal-5' Phosphate (PLP) — -254.96; -564.27; 3.13; -397.72 ng/mL — p=0.0285
Ameloblastoma · BRAF Gene Mutation
Primary: Tumor Response — 0; 0; 0; 0 Participants
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
Primary: Number of Participants With Dose-limiting Toxicities (DLT) — 0 Participants
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 5 Percentage of participants
Phelan McDermid Syndrome
Primary: ABC - Social Withdrawal Subscale — 10.31; 4.6; 14.8; 6.2 score on a scale
Hypophosphatasia
Primary: Effect of Asfotase Alfa Treatment on Skeletal Manifestations of Hypophosphatasia (HPP) — 2.00 scores on a scale
Malignant Melanoma
Primary: BRAF Mutation Status According to Cobas 4800 BRAF V600 Mutation Test vs. INCa Laboratories Molecular Genetics Laboratories — 150; 143; 264; 266 number of samples
TSC1 · TSC2 · Tuberous Sclerosis Complex
Primary: Objective Response Rate — 2 Participants
Cancer
Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants
Hypogonadism
Primary: Percent Change in Bone Mineral Density (BMD) According to rs700518 Polymorphism in the CYP19A1 Gene — 3.69; 4.13; 3.82; 0.38 percent change — p=<0.05
BRAF V600E Mutation
Primary: Number of Participants With Partial Response to Dabrafenib and Trametinib — 4 Participants
Solid Tumors
Primary: Time From Patient Recruitment to Final Results ≤ 21 Days in ≥ 90% of Patients — 21 calendar days
Prostate Cancer
Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants
Hepatocellular Carcinoma
Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale